{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fuh-Ngwa V"],"funding":["National Health and Medical Research Council of Australia","National Health and Medical Research Council investigator grant L1","Multiple Sclerosis Australia","Kate-Scott Memorial Scholarship","Henry Baldwin Trust and the Medical Research Future Fund","Macquarie Foundation Multiple Sclerosis Research Australia Senior Clinical Research Fellowship"],"pagination":["11584"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10354053"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["The indirect contribution of multiple sclerosis (MS) relapses to disability worsening outcomes, and vice-versa, remains unclear. Disease modifying therapies (DMTs) are potential modulators of this association. Understanding how these endo-phenotypes interact may provide insights into disease pathogenesis and treatment practice in relapse-onset MS (ROMS). Utilising a unique, prospectively collected clinical data from a longitudinal cohort of 279 first demyelinating event cases followed for up to 15 years post-onset, we examined indirect associations between relapses and treatment and the risk of disability worsening, and vice-versa. Indirect association parameters were estimated using joint models for longitudinal and survival data. Early relapses within 2.5 years of MS onset predicted earl"],"journal":["Scientific reports"],"pubmed_title":["The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-centre, longitudinal cohort study."],"pmcid":["PMC10354053"],"funding_grant_id":["GNT1173155","EPCP000008","APP1127819"],"pubmed_authors":["Simpson-Yap S","Ponsonby AL","Taylor BV","Fuh-Ngwa V","Lechner-Scott J","van der Mei I","Broadley SA","Charlesworth JC","Melton PE","Zhou Y"],"additional_accession":[]},"is_claimable":false,"name":"The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-centre, longitudinal cohort study.","description":"The indirect contribution of multiple sclerosis (MS) relapses to disability worsening outcomes, and vice-versa, remains unclear. Disease modifying therapies (DMTs) are potential modulators of this association. Understanding how these endo-phenotypes interact may provide insights into disease pathogenesis and treatment practice in relapse-onset MS (ROMS). Utilising a unique, prospectively collected clinical data from a longitudinal cohort of 279 first demyelinating event cases followed for up to 15 years post-onset, we examined indirect associations between relapses and treatment and the risk of disability worsening, and vice-versa. Indirect association parameters were estimated using joint models for longitudinal and survival data. Early relapses within 2.5 years of MS onset predicted earl","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-05-28T11:07:56.965Z","creation":"2024-11-12T18:31:37.78Z"},"accession":"S-EPMC10354053","cross_references":{"pubmed":["37463930"],"doi":["10.1038/s41598-023-38415-z"]}}